Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PHSRN peptide is a synthetic pentapeptide consisting of the amino acid sequence Proline-Histidine-Serine-Arginine-Asparagine. It is derived from the synergy site of fibronectin, a major extracellular matrix protein involved in cell adhesion and migration. PHSRN acts as a ligand for integrin α5β1, working cooperatively with the RGD (Arg-Gly-Asp) sequence to enhance cell-matrix interactions. In the field of ophthalmology, PHSRN peptide is being developed as a topical eye drop treatment for intractable corneal epithelial disorders and persistent corneal epithelial defects (PED). By promoting the migration and adhesion of corneal epithelial cells, the peptide facilitates the closure of non-healing wounds on the ocular surface. Clinical development is primarily centered in Japan, notably through research at Osaka University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PHSRN peptide.